Mechanism overview and target mining of atherosclerosis: Endothelial cell injury in atherosclerosis is regulated by glycolysis (Review)

RUIYING WANG1-5, MIN WANG1-5, JINGXUE YE1-5, GUIBO SUN1-5 and XIAOBO SUN1-5

1Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 2Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 3Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 4Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 5Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, P.R. China

Received August 14, 2020; Accepted November 5, 2020

DOI: 10.3892/ijmm.2020.4798

Abstract. Atherosclerosis (AS) is a chronic disease with a complex pathology that may lead to several cardiovascular and cerebrovascular diseases; however, further research is necessary to fully elucidate its pathogenesis. The main risk factors for AS include lipid metabolism disorders, endothelial cell injury, inflammation and immune dysfunction, among which vascular endothelial cell damage is considered as the main trigger for AS occurrence and development. Endothelial cell damage leads to enhanced intimal permeability and leukocyte adhesion, promoting thrombus formation and accelerating disease progression. The function of endothelial cells is affected by glycolysis regulation, since 80% of ATP in these cells is produced via this pathway. Genes associated with AS and endothelial cell glycolysis, including AKT1, interleukin-6, vascular endothelial growth factor A, TP53, signal transducer and activator of transcription 3, SRC and mitogen-activated protein kinase 1, were screened. Through integrated analysis, these genes were found to play a key role in AS by regulating multiple signaling pathways associated with cell signal transduction, energy metabolism, immune function and thrombosis.

In conclusion, endothelial cell injury in AS may be alleviated by glycolysis and is a potential clinical treatment strategy for AS.

Contents
1. Introduction
2. Factors implicated in AS
3. Vascular endothelial cells
4. Glycolysis
5. Prediction and analysis of targets associated with endothelial cell glycolysis in AS
6. Discussion

1. Introduction

Atherosclerosis (AS) is a chronic disease with complex etiology, which involves early local injury of the arterial intima, followed by lipid deposition, proliferation of the intimal fibrous tissue, local thickening of the intima and, ultimately, plaque formation (1). Vascular plaque-induced stenosis by AS may lead to insufficient arterial blood supply and cardiovascular diseases (2). The most serious complications caused by plaque rupture are myocardial infarction, cerebral ischemia, and ischemia of the surrounding tissue (3). The pathogenesis of AS has not been fully elucidated to date. Previous studies have demonstrated that AS is associated with lipid metabolism disorders, endothelial cell damage, inflammation and immune dysfunction, involving macrophages, endothelial cells, vascular smooth muscle cells and platelets (4,5). In recent years, AS animal models mainly include mice, rabbits, miniature pigs, non-human primates and transgenic animals (6). AS is a vicious circle combining multiple factors and long-term
effects. So, elucidating the underlying mechanism is crucial for the treatment and prevention of the disease.

Despite not having been fully elucidated, it is believed that lipid metabolism disorders, endothelial cell injury, inflammation and immune dysfunction are the most important factors implicated in the pathogenesis of AS (5,7). Functional damage of endothelial cells is the initiating step in the early stage of AS (8). Endothelial cell damage in AS plaques leads to further plaque instability, rupture (9) and secondary thrombosis, thus accelerating disease progression and affirming the important role of endothelial cell integrity (10). Glycolysis, the most important energy source for endothelial cells, is used to quickly produce energy, enabling cells to respond to environmental changes (11). Intermediate metabolic products produced during glycolysis affect cell survival (12); therefore, glycolytic rates in endothelial cells play a key role in maintaining their homeostasis and reducing the risk for AS.

The aim of the present study was to review the pathogenesis of AS, the role of endothelial cell damage and glycolysis, and the role of associated target genes and the involved signalling pathways, in order to indicate new approaches to the research on AS pathogenesis and intervention methods, and aid in the development of novel treatments for AS.

2. Factors implicated in AS

Pathogenesis. The pathogenesis of AS is extremely complicated (Fig. 1). AS is currently considered to be the result of the interaction among various mechanisms, including lipid metabolism disorder, inflammatory cell infiltration, oxidative stress, immune dysfunction and vascular endothelial cell damage, the latter of which ultimately leads to plaque rupture and thrombosis, leading to serious cardiovascular and cerebrovascular diseases (1,4,13).

Role of oxidative stress in AS. Oxidative stress is the initiating factor of AS inflammatory response, with reactive oxygen species (ROS) and oxidized low-density lipoprotein (Ox-LDL; formed by oxidative modification of LDL) being the main factors responsible for endothelial cell damage and for inducing the expression of pro-inflammatory factors in endothelial cells (14,15). When endothelial cells are continuously exposed to external as well as endogenous oxidants, oxidative stress is likely to induce production of various biologically active substances, which may cause endothelial cell functional damage and apoptosis (16,17). This process leads to the synthesis and release of inflammatory factors, further aggravating vascular inflammation (18). In addition, oxidative stress regulates the expression of vascular wall genes by acting on transcription factors of the vascular wall cells. For example, intracellular ROS directly oxidatively modify the transcription factor itself, thereby participating in the occurrence and development of AS (14).

Role of lipid metabolism disorder in AS. Excessive blood lipid levels are the main cause of AS. In the hyperlipidemic state, the elevated plasma LDL cholesterol (LDL-C) is deposited on the vascular intima and enters macrophages via membrane receptors (19). In addition, LDL also undergoes oxidative modification to form Ox-LDL, leading to changes in endothelial cell function, and causing increased permeability and lipid deposition in the inner membrane (20). Ox-LDL exhibits strong affinity for scavenger receptors found on mononuclear macrophages, leading to its quick internalisation (21). However, Ox-LDL is toxic for macrophages, causing them to become activated, rapidly proliferate, aggregate and degenerate (22). Finally, the macrophages undergo apoptosis and become foam cells, which then aggregate to form AS lipid plaques. Moreover, Ox-LDL binds to vascular endothelial cells through lectin-like oxidized LDL receptor-1 to disrupt intracellular signaling and cause endothelial cell dysfunction (23). Ox-LDL can also promote the continuous proliferation of vascular smooth muscle cells and their outward migration to form plaques on the inner wall of blood vessels.

Role of endothelial cell injury in AS. Disruption of endothelial cell morphology and function leads to vascular barrier function impairment, as well as to changes in the intimal integrity and permeability (24). The apoptosis and shedding of endothelial cells promote the adhesion and aggregation of platelets from the blood (25). Dysfunctional endothelial cells, macrophages and platelets secrete a variety of growth factors and vasoactive substances, stimulating the continuous proliferation of smooth muscle cells in the media, and enter the intima, while also causing contractions of the vascular wall (26). As a result, the fatty plaques increase in size while the lumen becomes progressively narrowed, promoting the formation of AS lesions (8).

Role of inflammation in AS. AS involves not only lipid deposition in blood vessel walls, but also chronic inflammation (27). Oxidative stress persists throughout AS. AS has been proven to be a chronic inflammatory disease initiated in the arterial wall, mainly driven by modification of endogenous structures and dysfunction of the vascular endothelium (28). Certain lipids act as signaling molecules, and bind to cell receptors to activate the expression of specific genes and produce a number of pro-inflammatory cytokines (19). This leads to an increase in the numbers of inflammatory cells, including macrophages, increased phagocytosis of Ox-LDL and production of pro-inflammatory factors, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-8 (29). These factors further aggravate the pathology of AS.

Role of immune dysfunction in AS. AS is also an autoimmune disease, stimulated by accumulated lipoproteins, as well as specific T lymphocytes and their antibodies, in the blood vessel wall (30). It was previously demonstrated that T lymphocytes infiltrate the aorta, where they accumulate and express restricted T-cell receptors, thereby promoting AS through immune regulation (13). In addition, the cells of innate immune response, such as monocytes and neutrophils, play an important role in the occurrence and development of AS (31). Upon immune function impairment, these cells disrupt cytokine production (27). Thus, the expression of anti-inflammatory factors decreases and the expression of pro-inflammatory factors increases, ultimately promoting AS development (29).

Role of microRNAs (miRNA) of the circulatory system in AS. miRNAs are found in non-coding regions of the genome and
play important roles in gene transcription, post-transcriptional processing, cell proliferation, cell differentiation, cell apoptosis, ontogeny, heredity and epigenetics (21,23). It has been recently discovered that miRNAs are involved in inflammatory cell regulation and, thus, all aspects of AS pathology, including vascular endothelial cell and monocyte development, differentiation and function (32). Studies have shown that miR-143 can affect the formation of AS plaques by inhibiting endothelial cell glycolysis, while miR-33 is closely associated with macrophage metabolism (33,34).

**Drug intervention for AS.** The aim of currently available anti-AS treatments, which mainly include statins, antithrombotic drugs and surgical intervention, is to reduce serum LDL levels (35). Statins are methylglutaryl-CoA reductase inhibitors that have been found to be effective at halting disease progression and reducing the incidence of cardiovascular and cerebrovascular complications. By inhibiting methylglutaryl-CoA reductase, statins lower total cholesterol and LDL-C, increase HDL-C, activate nitric oxide (NO) synthase, increase endothelial NO levels, and prevent NO decrease caused by Ox-LDL (36). Probucol, a strong synthetic antioxidant, is a symmetrical di-tert-butylphenol structure that is easily oxidized, thus reducing free oxygen radicals and diminishing their oxidizing capacity (37).

The irreversible antioxidant effect of probucol is attributed to its strong affinity for LDL-C, thus inhibiting LDL-C and reducing the formation of Ox-LDL. Anti-platelet aggregation drugs may also exert an anti-inflammatory effect on the injured vascular intima (38).

The combination of statins and antioxidants may prevent thrombosis and AS plaque formation (39). In addition, niacin, a broad-spectrum lipid-modulating drug, acts by inhibiting the expression of serum adhesion molecules and inflammatory cytokines (40). The anti-inflammatory effect of niacin is achieved by downregulating the NF-κB signaling pathway.

In addition to Western medicine, Traditional Chinese Medicine (TCM) has also achieved marked benefits in the treatment of AS. In TCM, AS is commonly categorized as ‘blood stasis’ and ‘phlegm turbidity’ (41). Modern TCM theories mostly attribute the pathogenesis of AS to phlegm, toxins and stasis. TCM arrests AS progression by activating blood and dredging collaterals, inhibiting inflammation and plaque formation, and stabilizing plaques (42,43). Commonly used TCM agents include Chaihu Shugan San, Yiqi Yangyin Recipe, Danhuang Tongmai Capsule and Simiao Yongan Decoction (44-46). From a macro perspective, TCM is guided by Chinese medicine principles, and the treatment is performed holistically. In recent years, TCM has been found to add unique advantages to the treatment of complex diseases, such as AS.

3. **Vascular endothelial cells**

**Physiological functions of vascular endothelial cells.** The inner vascular endothelium in the heart, blood and lymphatic vessels is composed of squamous epithelial cells, and is important for maintaining the complete structure and function of the blood vessel wall (47). Endothelial cells serve not only
as a mechanical barrier, but also as receptors and endocrine organs, as they are capable of synthesizing and releasing a variety of endothelial-derived vasoactive factors (9). When damaged, vascular endothelial cells secrete a variety of molecules to promote leukocyte adhesion. They also secrete endothelium-dependent factors, such as endothelin, angiotensin, NO and prostacyclin, regulating vasoconstriction and vasodilation (48). Endothelium-dependent dilation factors may also inhibit platelet activation and aggregation. Plasma plasminogen activator synthesized by vascular endothelial cells has high affinity for fibrin and can activate plasminogen to dissolve thrombi (24). Under normal conditions, these cells reduce inflammation by regulating the release of various cytokines and inflammatory factors, such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and monocyte chemokines (49). However, the injured endothelium promotes a series of inflammatory reactions, causing endothelial cell dysfunction and favouring AS development.

**Mechanism underlying the development of AS caused by vascular endothelial cell injury.** Vascular endothelial cell function is closely associated with AS, which is a chronic inflammatory response of the arterial wall to endothelial cell injury (8). Vascular endothelial cell injury and functional damage serve as the initiating factor. The dysfunction and morphological damage of endothelial cells may manifest as a variety of endothelial abnormalities, causing leukocyte adhesion, vasoconstriction, platelet activation, oxidative stress and inflammation, followed by thrombus formation which, in turn, promotes the formation of AS plaques (24,25,50,51). Endothelial progenitor cells participate in reendothelialization and angiogenesis, and may play a pivotal role in the occurrence and development of AS (52).

**Increased intimal permeability.** Following endothelial cell injury, lipids accumulate in the blood vessels, resulting in increased permeability of the vascular intima. This causes monocytes and phagocytes to be released into the bloodstream, increasing the adhesion to endothelial cells (50). LDL is then oxidized to the cytotoxic Ox-LDL, which is damaging to endothelial and smooth muscle cells. Macrophage Ox-LDL uptake occurs through scavenger receptors, accelerating their transformation into foam cells that eventually form the AS plaques (47).

**Increased leukocyte adhesion.** Leukocytes, particularly monocytes, adhere to the endothelium through intercellular adhesion molecules, leukocyte adhesion molecules, TNF-α and vascular cell adhesion molecules. Subsequently, guided by chemokines, they migrate to the intima and differentiate into macrophages (53). Macrophages secrete a variety of inflammatory factors, such as TNF-α, IL-1 and IL-6, to promote the formation of AS plaques. In addition, damage to endothelial cells leads to increased expression of adhesion molecules, while also increasing the susceptibility of endothelial cells to inflammatory stimuli. This again increases the expression of adhesion molecules, promoting the adhesion of monocytes to endothelial cells and triggering AS development (34).

**Promoting thrombosis.** Stimulation or damage of endothelial cells causes a decrease in their antithrombotic properties, which promotes thrombus formation (25). Among other factors, increased secretion of the von Willebrand factor and thromboxane mediated platelet aggregation and adhesion to the endothelium to promote thrombosis, while plasminogen activator inhibitors inhibit thrombolysis (5). Thus, the microthrombi formed on the endothelial inner membrane are difficult to dissolve, contributing to the formation of plaques (8).

**Regulation of endothelial progenitor cells.** Endothelial progenitor cells, a type of precursor cell with a high proliferation potential, are a heterogeneous cell population with multiple origins and different phenotypes, capable of producing endothelial cells (54). Endothelial progenitor cells can selectively be recruited to damaged or ischemic areas by stress and inflammatory stimuli to form new blood vessels through differentiation and proliferation, without relying on the original vasculature (55). Inflammation is the pathophysiological basis of various cardiovascular diseases. Pro-inflammatory cytokines stimulate the expression of adhesion molecules on the surface of endothelial cells and promote the onset of AS (56). Inflammation can stimulate the release of endothelial progenitor cells from the bone marrow into peripheral blood, thus promoting tissue repair (57). Therefore, the occurrence of AS is associated with endothelial progenitor cells, which are involved in repair and intimal hyperplasia following endothelial cell injury, which also promote the formation and stability of AS plaques (52).

**4. Glycolysis.**

It was previously demonstrated that 85% of ATP in endothelial cells is produced by glycolysis, of which ~60% is used for homeostatic maintenance and 40% for proliferation (11). The high glycolytic properties of endothelial cells result from their low content of mitochondria, which comprise only 5% of the cell. Although endothelial cells reside in a high-oxygen environment, they consume little oxygen and can, therefore, deliver oxygen to nearby tissues (58). Endothelial cells use glycolysis to quickly produce energy, which helps them adapt to changes in their environment. More metabolic intermediate products are produced through glycolysis, affecting cell survival (59). Compared with other cells, resting endothelial cells have a high-efficiency glycolysis rate. When cells undergo migration or proliferation, their glycolysis rates double (60). Glycolysis is required to meet the energy demands of blood vessel sprouting, since the apical cells at the front must continuously migrate forward to form filamentous or laminar pseudopodia, while stem cells at the back increase their proliferation rate and form a lumen (61). Endothelial cell dysfunction caused by Ox-LDL and other factors is the main cause of AS. It was previously demonstrated that excessive activation of glycolysis is a key factor leading to endothelial cell dysfunction and proliferation (12). Maintaining the metabolic balance of endothelial cells by inhibiting glycolysis to reduce dysfunction and inflammation may represent a novel treatment strategy for AS (11). The rate-limiting enzymes of glycolysis may be a bridge to elucidating the association between endothelial cell injury and AS.

Under physiological conditions, cells metabolize glucose mainly through oxidative phosphorylation, while
the glycolytic pathway is activated only under hypoxic conditions (62). The glycolytic pathway comprises a series of enzymatic reactions in which glucose from tissues is degraded (63). Glucose is first transported into the cell via glucose transporters (GLUTs), and is then phosphorylated by hexokinase (HK) into glucose-6-phosphate, which cannot penetrate the cell membrane (64). Glucose-6-phosphate is then converted into pyruvate by hexose phosphate isomerase and phosphofructokinase (PFK) (65). The pyruvate produced through glycolysis may directly enter the tricarboxylic acid cycle or be converted into lactic acid by lactate dehydrogenase (LDHA) (66). The lactic acid is then transported outside the cell via the monocarboxylic acid transporter 2 (67). The ATP produced by this process provides energy for the cell.

**Regulation of HK in endothelial glycolysis.** HK is the first rate-limiting enzyme in the glycolytic pathway. This enzyme catalyses the conversion of glucose to glucose-6-phosphate, and produces ATP through oxidative phosphorylation or glycolysis (68). It was previously demonstrated that the AKT/mTOR signalling pathway is associated with HK production. High HK expression in endothelial cells facilitates efficient glycolysis and promotes rapid cell proliferation (69). In addition, HK can bind to voltage-dependent anion channels in the outer mitochondrial membrane to prevent binding of the pro-apoptotic protein Bax. This prevents the release of cytochrome c from the mitochondria, thereby exerting an anti-apoptotic effect (70). Therefore, HK not only promotes cell proliferation, but also inhibits cell apoptosis.

**Regulation of PFK in endothelial glycolysis.** PFK, the second glycolytic rate-limiting enzyme in the glycolytic pathway, catalyses the conversion of fructose-6-phosphate to fructose 1,6-diphosphate. The expression of PFK is regulated by a number of factors, such as e-Src activation and hypoxia-inducible factor (HIF)-1α, promoting PFK2 expression (71). TP53-induced glycolysis and apoptosis regulator (TIGAR) may reduce PFK expression and inhibit glycolysis. The kinase activity of PFKFB3, a subtype of PFK2, in vascular endothelial cells, is affected by the RAS and AMP-activated protein kinase (AMPK) signalling pathways (72). In addition, PFKFB3 can also promote endothelial cell inflammation through TNF-α, thereby promoting AS development (73).

**Regulation of PK in endothelial glycolysis.** PK, the third rate-limiting enzyme in the glycolytic pathway, specifically catalyses the conversion of phosphoenolpyruvate to pyruvate. This irreversible reaction is a crucial regulatory step in the glycolytic pathway. PKM2 is the only PK subtype that can switch between high-activity (tetramer) and low-activity (dimer) forms. Following phosphorylation, PKM2 is converted to a dimer, promoting the upstream glycolytic products of PK to enter the biosynthetic pathway (74). In addition, the expression of PKM2 is differentially regulated by the PI3K/AKT signalling pathway (75). PKM2-regulated glycolysis contributes to the proliferation and migration of vascular smooth muscle cells, and is positively correlated with AS development (12).

**Regulation of LDHA in endothelial glycolysis.** LDHA, the fourth rate-limiting enzyme in the glycolytic pathway, catalyses the production of lactic acid from pyruvate. This enzyme enables recycling of pyruvate and reduced nicotinamide purine dinucleotide, and plays a key role in promoting efficient cell glycolysis (76). SRC can also phosphorylate LDHA and promote conversion enzyme activity. HIF-1α is the upstream regulator of LDHA, and both HIF-1α and LDHA stimulate the inflammatory response (77).

5. Prediction and analysis of targets associated with endothelial cell glycolysis in AS

**Target prediction.** Although endothelial cell glycolysis plays an important role in AS, related research is scarce. Therefore, in the present study, the term ‘NCBI-gene’ was used to search for genes associated with endothelial cell glycolysis in AS, and 76 genes were identified (Table I). The Comparative Toxicogenomics Database (CTD) is a database used to describe the association between chemical substances, genes and human diseases. CTD was used to conduct Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis (Table II); the pathways included in the analysis were the immune system pathway, the signal transduction pathway, pathways in cancer, the PI3K/AKT, IL-4, IL-13, HIF-1, NGF and FoxO signalling pathways, the platelet activation, signalling and aggregation pathway, as well as the fluid shear stress and AS pathways.

The screened genes play important regulatory roles in multiple signalling pathways, indicating that such interactions should also be present among their corresponding proteins. The STRING database, used to study the protein interaction networks, helps to mine core regulatory genes. Based on that, a protein-protein interaction network was built and Cytoscape 3.2.1 software (https://cytoscape.org/download_old_versions.html) was used to visualize it (Fig. 2). The node size in Fig. 1 reflects its importance in the network. CytoHubba is a network analysis plug-in specifically used to identify key nodes in the Cytoscape software, providing a variety of key node identification algorithms, which focus on different network topology characteristics. To make the identification of key targets as accurate as possible, the top 10 key targets were identified based on two algorithms, namely Matthews correlation coefficient (MCC) and Stress (Fig. 3). Next, the intersection of the two results was considered as the key targets for AS endothelial glycolysis, including AKT1, IL-6, vascular endothelial growth factor (VEGF)A, TP53, signal transducer and activator of transcription 3 (STAT3), SRC and mitogen-activated protein kinase (MAPK).1.

**Target analysis.** All 7 predicted targets are factors proven to promote or inhibit the process of AS. AKT1 and TP53 can directly regulate glycolysis, thereby affecting AS. In addition to the regulation of glycolysis, IL-6 can also regulate AS through inflammation; VEGFA, STAT3 and SRC are also closely associated with immune system dysfunction. The regulatory effect of MAPK1 on AS is mainly mediated through immune response, but the association between glycolysis and MAPK1 has not been explored. The available research on these 7 targets is currently not sufficient, and further experiments are required to verify the results. The purpose of the present review was also to provide a direction for future AS studies.
Table I. Gene information on atherosclerosis and endothelial cell glycolysis.

| No. | Gene name   | Full name                                      | Chromosome | Location   | ID       |
|-----|-------------|------------------------------------------------|------------|------------|----------|
| 1   | VEGFA       | Vascular endothelial growth factor A           | 6          | 6p21.1     | 7422     |
| 2   | CXCL8       | C-X-C motif chemokine ligand 8                | 4          | 4q13.3     | 3576     |
| 3   | PPARG       | Peroxisome proliferator activated receptor gamma | 3          | 3p25.2     | 5468     |
| 4   | IL33        | Interleukin 33                                 | 9          | 9p24.1     | 90865    |
| 5   | IL6         | Interleukin 6                                  | 7          | 7p15.3     | 3569     |
| 6   | HIF1A       | Hypoxia-inducible factor 1 subunit alpha       | 14         | 14q23.2    | 3091     |
| 7   | TP53        | Tumor protein p53                               | 17         | 17p13.1    | 7157     |
| 8   | KDR         | Kinase insert domain receptor                  | 4          | 4q12       | 3791     |
| 9   | TGFBI       | Transforming growth factor beta 1              | 19         | 19q13.2    | 7040     |
| 10  | mir21       | MicroRNA 21                                    | 17         | 17q23.1    | 406991   |
| 11  | CDKN2A      | Cyclin-dependent kinase inhibitor 2A            | 9          | 9p21.3     | 1029     |
| 12  | IL1B        | Interleukin 1 beta                             | 2          | 2q14.1     | 3553     |
| 13  | AKT1        | AKT serine/threonine kinase                    | 14         | 14q32.33   | 207      |
| 14  | BCL2        | BCL2 apoptosis regulator                       | 18         | 18q21.33   | 596      |
| 15  | SIRT1       | Sirtuin 1                                      | 10         | 10q21.3    | 23411    |
| 16  | STAT3       | Signal transducer and activator of transcription 3 | 17         | 17q21.2    | 6774     |
| 17  | TLR4        | Toll-like receptor 4                           | 9          | 9q33.1     | 7099     |
| 18  | PTGS2       | Prostaglandin-endoperoxide synthase 2          | 1          | 1q31.1     | 5743     |
| 19  | ADIPOQ      | Adiponectin C1Q and collagen domain containing | 3          | 3q27.3     | 9370     |
| 20  | NFE2L2      | Nuclear factor erythroid 2 like 2              | 2          | 2q31.2     | 4780     |
| 21  | NOTCH1      | Notch receptor 1                               | 9          | 9q34.3     | 4851     |
| 22  | MTOR        | Mechanistic target of rapamycin kinase         | 1          | 1p36.22    | 2475     |
| 23  | CTNNB1      | Catenin beta 1                                 | 3          | 3p22.1     | 1499     |
| 24  | PTEN        | Phosphatase and tensin homolog                 | 10         | 10q23.31   | 5728     |
| 25  | LEP         | Leptin                                         | 7          | 7q32.1     | 3952     |
| 26  | ESR1        | Estrogen receptor 1                            | 6          | 6q25.1-q25.2 | 2099 |
| 27  | SOD1        | Superoxide dismutase 1                         | 21         | 21q22.11   | 6647     |
| 28  | MAPK1       | Mitogen-activated protein kinase 1             | 22         | 22q11.22   | 5594     |
| 29  | RELA        | RELA proto-oncogene NF-kb subunit              | 11         | 11q13.1    | 5970     |
| 30  | miR34A      | MicroRNA 34a                                   | 1          | 1p36.22    | 407040   |
| 31  | IFNG        | Interferon gamma                               | 12         | 12q15      | 3458     |
| 32  | AGTR1       | Angiotensin II receptor type 1                 | 3          | 3q24       | 185      |
| 33  | ABCB1       | ATP-binding cassette subfamily B member 1      | 7          | 7q21.12    | 5243     |
| 34  | CD44        | CD44 molecule (Indian blood group)             | 11         | 11p13      | 960      |
| 35  | STAT1       | Signal transducer and activator of transcription 1 | 2          | 2q32.2     | 6772     |
| 36  | HGF         | Hepatocyte growth factor                       | 7          | 7q21.11    | 3082     |
| 37  | NAMPT       | Nicotinamide phosphoribosyl transferase        | 7          | 7q22.3     | 10135    |
| 38  | CYBB        | Cytochrome b-245 beta chain                    | X          | Xp21.1-p11.4 | 1536 |
| 39  | KL          | Klotho                                         | 13         | 13q13.1    | 9365     |
| 40  | SRC         | SRC proto-oncogene non-receptor tyrosine kinase | 20         | 20q11.23   | 6714     |
| 41  | PPARA       | Peroxisome proliferator activated receptor alpha | 22        | 22q13.31   | 5465     |
| 42  | BSG         | Basigin (Ok blood group)                       | 19         | 19p13.3    | 682      |
| 43  | TXN         | Thioredoxin                                    | 9          | 9q31.3     | 7295     |
| 44  | NOS2        | Nitric oxide synthase 2                        | 17         | 17q11.2    | 4843     |
| 45  | FOXO3       | Forkhead box O3                                | 6          | 6q21       | 2309     |
| 46  | PRKCE       | Protein kinase C epsilon                       | 2          | 2p21       | 5581     |
| 47  | NR4A1       | Nuclear receptor subfamily 4 group A member 1  | 12         | 12q13.13   | 3164     |
| 48  | NOX4        | NADPH oxidase 4                                | 11         | 11q14.3    | 50507    |
| 49  | PRKAA1      | Protein kinase AMP-activated catalytic subunit alpha 1 | 5          | 5p13.1     | 5562     |
| 50  | miR210      | MicroRNA 210                                   | 11         | 11p15.5    | 406992   |
| 51  | MALAT1      | Metastasis-associated lung adenocarcinoma transcript | 11        | 11q13.1    | 378938   |
| 52  | IGF1R       | Insulin-like growth factor 1 receptor          | 15         | 15q26.3    | 3480     |
Table I. Continued.

| No. | Gene name     | Full name                        | Chromosome | Location     | ID    |
|-----|---------------|---------------------------------|------------|--------------|-------|
| 53  | AHR           | Aryl hydrocarbon receptor       | 7          | 7p21.1       | 196   |
| 54  | CD36          | CD36 molecule                   | 7          | 7q21.11      | 948   |
| 55  | EZH2          | Enhancer of zeste 2 polycomb repressive complex 2 subunit | 7          | 7q36.1       | 2146  |
| 56  | SIRT6         | Sirtuin 6                       | 19         | 19p13.3      | 51548 |
| 57  | IKBKB         | Inhibitor of nuclear factor kappa B kinase subunit beta | 8          | 8p11.21      | 3551  |
| 58  | miR122        | MicroRNA 122                    | 18         | 18q21.31     | 406906|
| 59  | UCP2          | Uncoupling protein 2            | 11         | 11q13.4      | 7351  |
| 60  | ENO1          | Enolase 1                       | 1          | 1p36.23      | 2023  |
| 61  | PPARGC1A      | PPARG coactivator 1 alpha       | 4          | 4p15.2       | 10891 |
| 62  | SNAI1         | Snail family transcriptional repressor 1 | 20         | 20q13.13     | 6615  |
| 63  | PPBP          | Pro-platelet basic protein      | 4          | 4q13.3       | 5473  |
| 64  | DICER1        | Dicer 1 ribonuclease III        | 14         | 14q32.13     | 23405 |
| 65  | TXNIP         | Thioredoxin-interacting protein | 1          | 1q21.1       | 10628 |
| 66  | IL22          | Interleukin 22                   | 12         | 12q15        | 50616 |
| 67  | TNFSF13B      | TNF superfamily member 13b      | 13         | 13q33.3      | 10673 |
| 68  | SREBF2        | Sterol regulatory element-binding transcription factor 2 | 22         | 22q13.2      | 6721  |
| 69  | miR497        | MicroRNA 497                    | 17         | 17p13.1      | 574456|
| 70  | miR206        | MicroRNA 206                    | 6          | 6p12.2       | 406989|
| 71  | TUG1          | Taurine upregulated 1           | 22         | 22q12.2      | 55000 |
| 72  | miR135B       | MicroRNA 135b                   | 1          | 1q32.1       | 442891|
| 73  | miR142        | MicroRNA 142                    | 17         | 17q22        | 406934|
| 74  | miR135A1      | MicroRNA 135a-1                 | 3          | 3p21.2       | 406925|
| 75  | miR148B       | MicroRNA 148b                   | 12         | 12q13.13     | 442892|
| 76  | miR30C1       | MicroRNA 30c-1                  | 1          | 1p34.2       | 407031|

Figure 2. Protein interaction network of endothelial glycolysis and AS. The round nodes represent genes associated with endothelial glycolysis and AS. The size of the node reflects the importance of the node in the network to a certain extent: The larger the node, the greater the connectivity of the node in the network, and vice versa. Gray lines represent the interaction between two nodes. AS, atherosclerosis.
Table II. Potential pathways of atherosclerosis and endothelial cell glycolysis.

| Pathway                                      | No. | Genes                                                                                                                                 |
|----------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------|
| Immune system                                | 36  | AKT1, BCL2, CD36, CD44, CTNNB1, CXCL8, CYBB, FOXO3, HGF, HIF1A, IFNG, IKBKB, IL1B, IL22, IL33, IL6, KL, MAPK1, MTOR, NOS2, NR4A1, PPBP, PRKCE, PTEN, PTGS2, RELA, SRC, STAT1, STAT3, TGFBI, TLR4, TNFSF13B, TP53, TXN, TXNIP, VEGFA |
| Signal transduction                          | 30  | AGTR1, AKT1, CTNNB1, CXCL8, CYBB, ESR1, FOXO3, HGF, HIF1A, IGF1R, IKBKB, IL6, KDR, KL, LEP, MAPK1, MTOR, NOTCH1, NR4A1, PPBP, PRKAA1, PRKCE, PTEN, RELA, SRC, STAT1, STAT3, TGFBI, TP53, VEGFA |
| Pathways in cancer                           | 23  | AGTR1, AKT1, BCL2, CDKN2A, CTNNB1, CXCL8, HGF, HIF1A, IGF1R, IKBKB, IL6, MAPK1, MTOR, NOX4, PRKAA1, RELA, SIRT1, SOD1, STAT3, TGFBI, TP53, VEGFA |
| PI3K-AKT signalling pathway                  | 17  | AKT1, BCL2, FOXO3, HGF, IGF1R, IKBKB, IL6, KDR, MAPK1, MTOR, NR4A1, PRKAA1, PTEN, RELA, TLR4, TP53, VEGFA |
| Cellular responses to stress                 | 17  | CDKN2A, CXCL8, CYBB, EZH2, HIF1A, IL6, MAPK1, MTOR, NOX4, PRKAA1, RELA, SIRT1, SOD1, STAT3, TGFBI, TP53, TXN, VEGFA |
| Interleukin-4 and 13 signalling              | 16  | AKT1, BCL2, CD36, CXCL8, FOXO3, HGF, HIF1A, IL1B, IL6, NOS2, PTGS2, STAT1, STAT3, TGFBI, TP53, VEGFA |
| HIF-1 signalling pathway                     | 15  | AKT1, BCL2, CYBB, ENO1, HIF1A, IFNG, IGF1R, IL6, MAPK1, MTOR, NOS2, RELA, SIRT1, SOD1, STAT3, TGFBI, TP53, VEGFA |
| Platelet activation, signaling and aggregation | 10  | AKT1, CD36, HGF, MAPK1, PPBP, PRKCE, SOD1, SRC, TGFBI, VEGFA |
| NGF signalling via TRKA from the plasma membrane | 12  | AKT1, FOXO3, HGF, KL, MAPK1, MTOR, NR4A1, PRKCE, PTEN, SRC, STAT3, TGFBI |
| Fluid shear stress and atherosclerosis       | 15  | AKT1, BCL2, CTNNB1, CYBB, IFNG, IKBKB, IL1B, KDR, NFE2L2, PRKAA1, RELA, SRC, TGFBI, TP53, TXN, VEGFA |
| FoxO signalling pathway                      | 11  | AKT1, FOXO3, IGF1R, IKBKB, IL6, MAPK1, PRKAA1, PTEN, SIRT1, STAT3, TGFBI |
| PI3K/AKT activation                          | 10  | AKT1, FOXO3, HGF, KL, MAPK1, MTOR, NR4A1, PTEN, SRC, TP53 |
| LAT2/NTAL/LAB on calcium mobilization        | 10  | AKT1, FOXO3, HGF, KL, MAPK1, MTOR, NR4A1, PTEN, SRC, TP53 |

Figure 3. Identification of key protein targets. The top 10 key targets were identified based on the two algorithms, namely (A) MCC and (B) Stress, in Cytoscape software. The size and color of the nodes reflect the importance of the target (the larger the size and the darker the color, the more important the target). MCC, Matthews correlation coefficient.
Evaluation of AKT1 involvement in endothelial cell glycolysis in AS. AKT, including AKT1, AKT2 and AKT3, play an important role in cell proliferation, survival, metabolism and migration (78). AKT can activate mTOR, another major regulatory gene of cell metabolism, thereby promoting the expression of HIF-1α. HIF-1α then regulates the expression of glycolysis-related proteins, such as GLUTs, PK, HK2 and LDHA (79). These pathways promote glucose uptake and lactic acid production. In addition, endothelial glycolysis can be regulated by the FKB51/AKT1 and AKT1/GSK3β signalling pathways (80,81). Therefore, as regards energy metabolism, AKT1 may be a key target in AS.

Evaluation of IL-6 involvement in endothelial cell glycolysis in AS. IL-6 is an important pro-inflammatory cytokine (82). Chronic inflammation is also considered as part of AS pathology, suggesting a possible role for IL-6 (83). It has been shown that IL-6 affects AS development through the acute phase response, and exerts an effect on insulin resistance (84), while it also promotes glycolysis through PFKFB3 (85). The IL-6/STAT3 pathway is also a pathway involved in glycolysis regulation (86).

Evaluation of VEGFA involvement in endothelial cell glycolysis in AS. VEGFA promotes angiogenesis and regulates endothelial cell proliferation, macrophage infiltration and foam cell formation through signal transduction (87); therefore, it plays a key regulatory role in the formation and stabilization of AS plaques (88). In addition, it was previously demonstrated that endothelial glycolysis may be promoted by enhancing VEGFA expression, making it an important contributor to AS development and endothelial glycolysis (89). Therefore, VEGFA is an important target in AS and endothelial glycolysis.

Evaluation of TP53 involvement in endothelial cell glycolysis in AS. TP53, also referred to as ‘the guardian of the genome’, maintains gene stability. As it is mutated in >50% of tumour cells, TP53 is used for cancer prediction and risk assessment (90). In addition, TP53 regulates energy metabolism through the AKT/mTOR and NF-xB signalling pathways, and it inhibits glycolysis by downregulating the expression of rate-limiting enzymes and activating TP53-induced glycolysis and TIGAR (91,92). It was previously demonstrated that endothelial autophagy is inhibited in advanced AS by regulating mTOR and TIGAR (93). However, there is insufficient research on AS endothelial glycolysis, and the TP53 regulatory effects in AS require further investigation.

Evaluation of STAT3 involvement in endothelial cell glycolysis in AS. STAT3, a transcription factor, regulates cell growth, apoptosis and inflammation, and plays an important role in cancer, AS, as well as cardiovascular and cerebrovascular diseases (94). STAT3 is also strongly associated with endothelial cell dysfunction, macrophage polarization and inflammatory responses, thereby promoting AS development (95). In addition, it can enhance cell metabolism through HK2 upregulation. Previous studies have demonstrated that the IL-6/STAT3 and JAK2/STAT3 pathways can promote glycolysis, confirming the crucial role of STAT3 in AS and glycolysis (96,97). Therefore, STAT3 was proven to be an important factor in AS and glycolysis.

Evaluation of SRC involvement in endothelial cell glycolysis in AS. SRC is an oncogene that regulates intracellular signal transduction, cell proliferation and cell migration (98). SRC phosphorylation and activation also participates in intracellular metabolic processes (99). It was previously demonstrated that the SRC/AKT/LKB1/AMPKα signalling pathway can shift the intracellular metabolic pathway from glycolysis to aerobic metabolism (100). In addition, SRC-related pathways in endothelial cells promote AS by affecting leukocyte adhesion and monocyte transport (101). Thus, SRC is another important target in AS and endothelial cell glycolysis.

Evaluation of MAPK1 involvement in endothelial cell glycolysis in AS. MAPK is an important intracellular enzyme and the upstream signalling transduction molecule of several pathways (102). It was previously demonstrated that the P38/MAPK signalling pathway can aggravate AS, while MAPK1 affects cell adhesion and the immune response to promote AS development (103). However, further research is required to confirm the regulatory role of MAPK1 in AS and endothelial cell glycolysis.

6. Discussion

Although some progress has been made in the treatment of AS and its complications, with a consequent improvement in patient survival (1), long-term illness puts pressure on the heart and is associated with a major socioeconomic burden (3). AS is currently considered as a chronic inflammatory disease, and the underlying mechanisms mainly involve oxidative stress, lipid metabolism disorders, endothelial cell damage, inflammation and immune dysfunction (5,27). Eventually, plaque rupture and thrombosis causes acute life-threatening cardiovascular and cerebrovascular diseases (1). Vascular endothelium inflammation and cell dysfunction are considered as the initiating and central events in AS (29). Since glycolysis is the main metabolic pathway in endothelial cells, an in-depth study of the association between endothelial cell glycolysis and AS may further elucidate AS pathophysiology and provide clues for its prevention (11).

Through mining and analysis of endothelial cell glycolysis and AS-related genes, 8 key targets were identified, namely AKT1, IL-6, VEGFA, TP53, STAT3, SRC and MAPK1. These targets were found to directly or indirectly affect the expression of key rate-limiting enzymes in endothelial cell glycolysis. In addition, the pathways obtained by the enrichment of these genes included the immune system pathway, the signal transduction pathway, pathways in cancer, the PI3K/AKT, IL-4, IL-13, HIF-1, NGF and FoxO signalling pathways, the platelet activation, signalling and aggregation pathway, as well as the fluid shear stress and AS pathways. The aforementioned results are based on existing research and correlation prediction (104). At present, research on AS mainly uses genetically modified animal models, such as ApoE⁻/⁻ and db/db mice, and the findings cannot yet be translated into clinical application. Therefore, these targets must be further verified before they reach the clinical stage. The aim of the present review was to...
contribute to the study of AS mechanisms and provide novel suggestions, since future AS therapies should be explored from a new perspective. Advanced science and technology, including high-content technology, single cell transcriptomics, lipometabolic technology and epigenetic modification technology, will hopefully accelerate the search for novel AS treatments.

Acknowledgements

Not applicable.

Funding

This review was supported by the National Natural Science Foundation of China (grant no. 81973514), the Central Public-Interest Scientific Institution Basal Research Fund (grant no. 2018PT35030) and the Drug Innovation Major Project (grant no. 2018ZX09711001-009).

Availability of data and materials

Not applicable.

Authors' contributions

GS and XS contributed to the conception and design of the study. RW performed the literature search and wrote the manuscript. MW prepared the figures. JY revised the manuscript. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kobiyama K and Ley K: Atherosclerosis. Circ Res 123: 1188-1120, 2018.
2. Spinelli FR, Barone F, Cacciapaglia F, Pecani A and Piga M: Atherosclerosis and autoimmunity. Mediators Inflamm 2018: 6730421, 2018.
3. Lu H and daugherty A: Atherosclerosis. Arterioscler Thromb Vasc Biol 35: 485-491, 2015.
4. Libby P, Buring JE, Badimon L, Hansson GK, deankin J, Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN and Rutledge JC: Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 63: 1-9, 2011.
5. Gupta M, Blumenthal C, Chatterjee S, Bandyopadhyay D, Jain V, Lave CJ, Virani SS, Ray KK, Arowo WS and Ghosh RK: Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opin Investig Drugs 29: 611-622, 2020.
6. Lee J, Jung S, Kim N, Shin MJ, Ryu DH and Hwang GS: Myocardial metabolic alterations in mice with diet-induced atherosclerosis: Linking sulfur amino acid and lipid metabolism. Sci Rep 7: 13997, 2017.
7. Novák J, Olejníková V, Tkáčová N and Santulli G: Mechanistic role of MicroRNAs in coupling lipid metabolism and atherosclerosis. Adv Exp Med Biol 887: 79-100, 2015.
8. Shao D, Lian Z, Di Y, Zhang L, Rajokka MSR, Zhang Y, Kong J, Jiang C and Shi J: Dietary compounds have potential in controlling atherosclerosis: Linking sulfur amino acid and lipid metabolism. Sci China Life Sci 61: 1024-1029, 2018.
9. Chen PY, Schwartz MA and Simons M: Endothelial-tomesenchymal transition, vascular inflammation, and atherosclerosis. Front Cardiovasc Med 7: 53, 2020.
10. Gao F, Chen J and Zhu H: A potential strategy for treating atherosclerosis: Improving endothelial function via AMP-activated protein kinase. Sci China Life Sci 61: 1024-1029, 2018.
11. Pircher A, Treps L, Bodrug N and Carmeliet P: Endothelial cell metabolism: A novel player in atherosclerosis? Basic principles and therapeutic opportunities. Atherosclerosis 253: 247-257, 2016.
12. Zhao X, Tan F, Cao X, Cao Z, Li B, Shen Z and Tian Y: PKM2 dependent glycolysis promotes the proliferation and migration of vascular smooth muscle cells during atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 52: 9-17, 2020.
13. Ilhan F and Kalkanli ST: Atherosclerosis and the role of immune cells. World J Clin Cases 3: 345-352, 2015.
14. Xiao W, Jia Z, Zhang Q, Wei C, Wang H and Wu Y: Inflammation and oxidative stress, rather than hypoxia, are predominant factors promoting angiogenesis in the initial phases of atherosclerosis. Mol Med Rep 12: 3315-3322, 2015.
15. Dinh QN, Chrissobolis S, Diep H, Chan CT, Ferens D, Drummond GR and Sobey CG: Advanced atherosclerosis is associated with inflammation, vascular dysfunction and oxidative stress, but not hypertension. Pharmacol Res 116: 70-76, 2017.
16. Yang K, Zhang H, Luo Y, Zhang J, Wang M, Liao P, Cao L, Guo P, Sun G and Sun X: Gypenoside XVII prevents atherosclerosis by attenuating endothelial apoptosis and oxidative stress: Insight into the ERK-Mediated PI3K/Akt pathway. Int J Mol Sci 18: 77, 2017.
17. Feletou M, Cohen RA, Vanhoutte PM and Verbeuren TJ: TF receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis. Adv Pharmacol 60: 85-106, 2010.
18. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN and Rutledge JC: Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 63: 1-9, 2011.
19. Gupta M, Blumenthal C, Chatterjee S, Bandyopadhyay D, Jain V, Lave CJ, Virani SS, Ray KK, Arowo WS and Ghosh RK: Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opin Investig Drugs 29: 611-622, 2020.
20. Lee J, Jung S, Kim N, Shin MJ, Ryu DH and Hwang GS: Myocardial metabolic alterations in mice with diet-induced atherosclerosis: Linking sulfur amino acid and lipid metabolism. Sci Rep 7: 13997, 2017.
21. Novák J, Olejníková V, Tkáčová N and Santulli G: Mechanistic role of MicroRNAs in coupling lipid metabolism and atherosclerosis. Adv Exp Med Biol 887: 79-100, 2015.
22. Shao D, Lian Z, Di Y, Zhang L, Rajokka MSR, Zhang Y, Kong J, Jiang C and Shi J: Dietary compounds have potential in controlling atherosclerosis: Linking sulfur amino acid and lipid metabolism. Sci China Life Sci 61: 1024-1029, 2018.
23. Giral H, Kratzer A and Landmesser U: MicroRNAs in lipid metabolism and atherosclerosis. Best Pract Res Clin Endocrinol Metab 30: 665-676, 2016.
24. Simons M: Endothelial-to-epithelial cell transition and the role of miRNAs. Am J Physiol Heart Circ Physiol 316: H179-H187, 2019.
25. Mudau M, Genis A, Lochner A and Strijdom H: Endothelial dysfunction and the pathobiology of atherosclerosis. Circ Res 118: 620-636, 2016.
26. Giral H, Kratzer A and Landmesser U: MicroRNAs in lipid metabolism and atherosclerosis. Best Pract Res Clin Endocrinol Metab 30: 665-676, 2016.
27. Simons M: Endothelial-to-epithelial cell transition and the role of miRNAs. Am J Physiol Heart Circ Physiol 316: H179-H187, 2019.
28. Mudau M, Genis A, Lochner A and Strijdom H: Endothelial dysfunction and the pathobiology of atherosclerosis. Circ Res 118: 620-636, 2016.
29. Giral H, Kratzer A and Landmesser U: MicroRNAs in lipid metabolism and atherosclerosis. Best Pract Res Clin Endocrinol Metab 30: 665-676, 2016.
30. Hansson GK and Hermansson A: The immune system in atherogenesis: Linking sulfur amino acid and lipid metabolism. Sci China Life Sci 61: 1024-1029, 2017.
31. Ikeda A, Okada M and Shibata T: Atherosclerosis and the role of immune cells. World J Clin Cases 3: 345-352, 2015.
32. Ilhan F and Kalkanli ST: Atherosclerosis and the role of immune cells. World J Clin Cases 3: 345-352, 2015.
33. Oquime M, Ediriweera HN, Gundra UM, Sheedy FJ, Ramkhelawon B, Hutchison SB, Rinehold K, van Solingen C, Fullerton MD, Cecchini K, et al. MicroRNA-33-dependent regulation of macrophage-mediated extracellular immune cell polarization in atherosclerosis. J Clin Invest 125: 4334-4348, 2015.

34. Kumar S, Kim CW, Simmons RD and Jo H: Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: Mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol 34: 2206-2216, 2014.

35. Barton AE: Anti-inflammatory and therapy of atherosclerosis and its clinical complications. Curr Opin Pharmacol 13: 149-153, 2013.

36. Gonzalez L and Trigatti BL: Macrophage apoptosis and necrotic core development in atherosclerosis: A rapidly advancing field with clinical relevance to imaging and therapy. Can J Cardiol 33: 32-42, 2017.

37. Chen C, Wang Y, Cao Y, Wang Q, Anwaier G, Zhang Q and Li TT, Wang ZB, Li Y, Cao F, Yang BY and Kuang HX: The discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. Eur J Pharmacol 868: 172871, 2020.

38. Dong Y, Fernandes C, Liu Y, Wu Y, Wu H, Brophy ML, Deng L, Chrysohoou C, Kollia N and Tousoulis D: The link between stress-induced dysfunction of in vitro cultured human endothelial cells: A novel perspective for the prevention and therapy of atherosclerosis. Oxid Med Cell Longev 2016: 12466458, 2016.

39. Jiang Y, Jin M, Chen J, Yan J, Liu P, Yao M, Cai W and Pi R: Disruption of the niacin-lipico acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. Eur J Pharmacol 868: 172871, 2020.

40. Ren Y, Qiao W, Fu D, Han Z, Liu W, Ye W and Liu Z: Traditional Chinese medicine protects against cytokine production as the potential immunosuppressive agents in atherosclerosis. J Immunol Res 2017: 7424307, 2017.

41. Li TT, Wang ZB, Li Y, Cao F, Yang BY and Kuang HX: The mechanisms of traditional Chinese medicine underlying the prevention and treatment of atherosclerosis. Chin J Nat Med 17: 401-412, 2019.

42. Tian F, Gu L, Si A, Yao Q, Zhang X, Zhao J and Hu D: Metabolomic study on the faecal extracts of atherosclerosis mice and its application in a traditional Chinese Medicine. J Chromatogr B Analyt Technol Biomed Life Sci 1007: 140-148, 2015.

43. Fan Q, Liu Y, Rao J, Zhang Z, Xiao W, Zhu C, Chai X, Ye K, Ning N, Yin Z, et al: Anti-atherosclerosis effect of angon niu huang pill via regulating Th17/Treg immune balance and inhibiting chronic inflammatory on Apoe-/- mice model of early and mid-term atherosclerosis. Front Pharmacol 10: 1584, 2020.

44. Zhu ZB, Song K, Huang WJ, Li H, Yang H, Bai YQ, Guo KT, Yang X, Zhang Z, Zhang CH, et al: Iron load exacerbates atherosclerosis and dyslipidemia with non-flushing effects. Eur J Pharmacol 868: 172871, 2020.

45. Deng F, Zhou R, Lin C, Yang S, Wang H, Li W, Zheng K, Lin W, Li X, Yao X, et al: Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer. Theranostics 9: 1001-1014, 2019.

46. Gottwey R and Quinlinn R: Skeletal muscle disorders of glycolysis and genolysis. Nat Rev Neurol 12: 393-402, 2016.

47. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Queupebeur A, Groeia J, et al: Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab 19: 37-48, 2014.

48. Fernie AR, Carrari F and Sweetlove LJ: Respiratory metabolism: Glycolysis, the TCA cycle and mitochondrial electron transport. Biochem J 344: 367-380, 2000.

49. Tang BL: Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol 235: 7653-7662, 2020.

50. Paik JY, Lee KH, Bo KH, Choe YS, Choi Y and Kim BT: Nitric oxide stimulates 18F-FDG uptake in human endothelial cells through increased hexokinase activity and GLUT1 expression. J Nucl Med 46: 365-370, 2005.

51. Kim JW, Gao P, Liu YC, Semenza GL and Fang C: Hypoxia-inducible factor 1 and regulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. J Biol Chem 272: 7381-7387, 1997.

52. Song J, Li Y, Song J, Hou F, Liu B and Li A: Mangiferin protects mitochondrial function by preserving mitochondrial hexokinase II in vessel endothelial cells. Biochim Biophys Acta Mol Basis Dis 1863: 1829-1839, 2017.

53. Wang Y, Han X, Fu M, Wang J, Song Y, Liu Y, Zhang J, Zhou J and Ge J: Qiliqiangxin attenuates hypoxia-induced injury in primary rat cardiac microvascular endothelial cells via promoting HIF-1α-dependent glycolysis. J Cell Mol Med 22: 1791-1803, 2018.

54. Wang Y, Han X, Fu M, Wang J, Song Y, Liu Y, Zhang J, Zhou J and Ge J: Qiliqiangxin attenuates hypoxia-induced injury in primary rat cardiac microvascular endothelial cells via promoting HIF-1α-dependent glycolysis. J Cell Mol Med 22: 1791-1803, 2018.

55. Wang Y, Han X, Fu M, Wang J, Song Y, Liu Y, Zhang J, Zhou J and Ge J: Qiliqiangxin attenuates hypoxia-induced injury in primary rat cardiac microvascular endothelial cells via promoting HIF-1α-dependent glycolysis. J Cell Mol Med 22: 1791-1803, 2018.
74. Lu S, Deng J, Liu H, Liu B, Yang J, Miao Y, Li J, Wang N, Jiang C, Xu Q, et al: PKM2-dependent metabolic reprogramming in CD4+ T cells is crucial for hyperhomocysteinemia-accelerated atherosclerosis. J Mol Med (Berl) 96: 585-600, 2018.

75. Zhang X, Chen B, Wu J, Sha J, Yang B, Zhu J, Sun J, Hartung J and Bao E: Aspirin enhances the protection of Hsp90 from heat-stressed injury in cardiac microvascular endothelial cells through PI3K-Akt and PKM2 pathways. Cells 9: 243, 2020.

76. Sernovanova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M, Moroz E, Khanin R, Satagopan J, Koutcher JA and Blasberg R: LDHA-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS One 13: e0203965, 2018.

77. Chen SF, Pan MX, Tang JC, Cheng J, Zhao D, Zhang Y, Liao HB, Liu R, Zhong X, Zhang ZF, et al: Arginase is neuroprotective through suppressing HIF-1α/LDHA-mediated inflammatory response after cerebral ischemia/reperfusion injury. Mol Brain 13: 63, 2020.

78. Fernández-Hernando C, József L, Jenkins D, Di Lorenzo A and Sessa WC: Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler Thromb Vasc Biol 29: 2033-2040, 2009.

79. Pan C, Liu Q and Wu X: HIF-1α/miR-520a-3p/AKT1/mTOR feedback promotes the proliferation and glycolysis of gastric cancer cells. Cancer Manag Res 11: 10145-10156, 2019.

80. Zhong ZW, Zhou WC, Sun XF, Wu QC, Chen WK and Miao CH: Dezocine regulates the malignant potential and aerobic glycolysis of liver cancer targeting Akt1/GSK-3β pathway. Ann Transl Med 8: 480, 2020.

81. Zhao X, Wu X, Wang H, Yu H and Wang J: USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBPS5-AKT1 signaling. Mol Carcinog 59: 1000-1011, 2020.

82. Song L and Schindler C: IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 177: 43-51, 2004.

83. Zhang P, Chen X, Zhang Y, Su H, Zhang Y, Zhou X, Sun M, Li L and Xu Z: Tett3 enhances IL-6 expression through up-regulation of 5-hmc in IL-6 promoter in chronic hypoxia induced atherosclerosis in offspring rats. Life Sci 232: 116601, 2019.

84. Bozic M, Alvarez A, de Pablo C, Sanchez-Niño M, Ortiz A, Dolcet X, Encinas M, Fernandez E and Valdivielso JM: Impaired vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: Implications for atherosclerosis development. PLoS One 10: e0136863, 2015.

85. Han J, Meng Q, Xi Q, Zhang Y, Zhuang Q, Han J, Yang J, Ding Q and Wu G: Interleukin-6 stimulates aerobic glycolysis by regulating PKFBF3 at early stage of colorectal cancer. Int J Oncol 48: 215-224, 2016.

86. Li H, Liang Q and Wang L: Icaritin inhibits glioblastoma cell invasion and cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. Vascul Pharmacol 112: 72-78, 2019.

8732-8744, 2019.

88. Li X, Wu L, Zopp M, Kopelov S and Du W: p53-TP53-Induced glycolysis regulator mediated glycolytic suppression attenuates DNA damage and genomic instability in fanconi anemia hematopoietic stem cells. Stem Cells 37: 937-947, 2019.

89. Chen Q, Lv J, Yang W, Xu B, Wang Z, Yu Z, Wu J, Yang Y and Han Y: Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics 9: 6424-6442, 2019.

90. Zhou X, Li D, Yan W and Li W: Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice. Int J Mol Sci 9: 2253-2264, 2008.

91. Ko YH, Domingo-Vidal M, Roche M, Lin Z, Whitaker-Menezes D, Seifert E, Capparelli C, Tuluc M, Birbe RC, Tassonne P, et al: TP53-inducible glycolysis and apoptosis regulator (TIGAR) mediates glucose metabolism and apoptosis in cancer cells. Cancer Research 75: 1041-1051, 2015.

92. Seki N, Hashimoto N, Taira M, Yagi S, Yoshida Y, Ishikawa K, Suzuki Y, Sano H, Horiuchi S, Yoshida S, et al: Regulation of Src homology 2-containing protein tyrosine phosphatase by advanced glycation end products: The role on atherosclerosis in diabetes. Metabolism 56: 1591-1598, 2007.

93. Park JS, Lee S, Jeong AL, Han S, Ka HI, Lim JS, Lee MS, Yoon DY, Lee JH and Yang Y: Hypoxia-induced IL-32β increases glycolysis in breast cancer cells. Cancer Lett 356: 800-808, 2015.

94. Nam K, Oh S and Shin I: Ablation of cd44 induces glycolysis-to-oxidative phosphorylation transition via modulation of the c-Src-Akt-LKB1-AMPK pathway. Biochim J 473: 3013-3030, 2016.

95. Zhou X, Li d, Yan W and Li W: Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice. Int J Mol Sci 9: 2253-2264, 2008.

96. Byun S, Jung H, Chen J, Kim YC, Kim DH, Kong B, Guo G, Kemper B and Kemper JK: Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. J Biol Chem 294: 8732-8744, 2019.

97. Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, Szmitko PE, Peterson MD, Gupta M, Al-Omran M and Verma S: Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: Translational implications for atherosclerosis. Am J Physiol Heart Circ Physiol 296: 1440-1449, 2009.

98. Gupta A, Mohanty P and Bhatnagar S: Integrative analysis of 19742-19750, 2019.

99. Ko YH, Domingo-Vidal M, Roche M, Lin Z, Whitaker-Menezes D, Seifert E, Capparelli C, Tuluc M, Birbe RC, Tassonne P, et al: TP53-inducible glycolysis and apoptosis regulator (TIGAR) mediates glucose metabolism and apoptosis in cancer cells. Cancer Research 75: 1041-1051, 2015.

100. Perrotta P, Emini Veseli B, Van der Veken B, Roth L, Martinet W and De Meyer GRY: Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. Vascul Pharmacol 112: 72-78, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.